Disc Medicine's Stock Plummets After FDA's Complete Response Letter for Bitopertin Disc Medicine, Inc. experiences a significant stock decline of 21.9% after receiving a Complete Response Letter from the FDA concerning bitopertin.

Disc Medicine's Stock Plummets After FDA's Complete Response Letter for Bitopertin #United_States #New_York #FDA #Disc_Medicine #Bitopertin